Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
AstraZeneca
Farmers Insurance
Boehringer Ingelheim
Merck
Mallinckrodt
QuintilesIMS
Harvard Business School
McKesson

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: RE41956

« Back to Dashboard

Summary for Patent: RE41956
Title:Dose setting limiter
Abstract: A limiting mechanism which prevents the setting of a dose, which exceeds the amount of liquid left in a cartridge of an injection device, is disclosed. The injection device is the type where a dose is set by rotating a dose setting member relative to a driver and away from a fixed stop in the injection device. The dose setting member interfaces the driver such that the dose setting member can be rotated in one direction without rotating the driver. The dose is injected by rotating back the dose setting member which during the backward rotation carries the driver with it. Rotating the driver causes the piston rod to move forward inside the cartridge and expel some of the liquid contained in the cartridge. The driver is provided with a track having a length which is related to the total amount of liquid in the cartridge and which track is engaged by a track follower coupled to the dose setting member to follow rotation of this dose setting member. Each time a dose is set and injected, the track follower moves further into the track. When the track follower reaches the end of the track the dose setting member can not be rotated further, and a dose larger than the remaining liquid in the cartridge cannot be set.
Inventor(s): Klitgaard; Peter Christian (Glostrup, DK), Hansen; Steffen (Hillerod, DK), Radmer; Bo (Hillerod, DK), Moller; Claus Schmidt (Fredensborg, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:11/122,211
Patent Claim Types:
see list of patent claims
Use; Device; Delivery;

Drugs Protected by US Patent RE41956

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novo Nordisk Inc NORDITROPIN NORDIFLEX somatropin recombinant INJECTABLE;INJECTION 021148-004 Oct 1, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NORDITROPIN NORDIFLEX somatropin recombinant INJECTABLE;INJECTION 021148-005 Oct 1, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NORDITROPIN NORDIFLEX somatropin recombinant INJECTABLE;INJECTION 021148-006 Oct 1, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NORDITROPIN NORDIFLEX somatropin recombinant INJECTABLE;INJECTION 021148-007 Mar 10, 2009 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc LEVEMIR FLEXPEN insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536-002 Jun 16, 2005 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLOG FLEXPEN insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-003 Jan 19, 2001 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLOG MIX 70/30 FLEXPEN insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-004 May 3, 2002 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc VICTOZA liraglutide recombinant SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLOG INNOLET insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-004 Apr 23, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE41956

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark1999 01309Sep 16, 1999

Non-Orange Book US Patents Family Members for Patent RE41956

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,582,404 Dose setting limiter ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent RE41956

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2383078 ➤ Subscribe
China 1374876 ➤ Subscribe
China 1183975 ➤ Subscribe
Czech Republic 20020927 ➤ Subscribe
Germany 20023735 ➤ Subscribe
Germany 20023819 ➤ Subscribe
Germany 60021425 ➤ Subscribe
Germany 60043595 ➤ Subscribe
Denmark 1250167 ➤ Subscribe
Denmark 1570876 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Colorcon
Federal Trade Commission
Merck
Johnson and Johnson
McKesson
Cerilliant
US Department of Justice
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot